Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 2/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | PLK4 | O00444 | 2/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 2/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | TTK | P33981 | 11/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.36 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4977505 | 0.93 | TTK (0.40) | FLT3PDGFRATTKPDE5A | |
| SCHEMBL4977877 | 0.92 | CSF1R (0.49) | MERTKCSF1RLRRK2FLT3PDGFRA | |
| SCHEMBL4974126 | 0.91 | TTK (0.45) | MERTKCSF1RPLK4NTRK1LRRK2 | |
| SCHEMBL4766859 | 0.87 | TTK (0.48) | CSF1RLRRK2FLT3PDGFRATTK | |
| SCHEMBL4766972 | 0.86 | PLK4 (0.36) | PLK4NTRK1LRRK2TTKEGFR | |
| SCHEMBL4977265 | 0.86 | TTK (0.49) | MERTKCSF1RLRRK2FLT3PDGFRA | |
| SCHEMBL4974257 | 0.85 | MERTK (0.40) | MERTKCSF1RPLK4NTRK1LRRK2 | |
| SCHEMBL4972483 | 0.83 | TTK (0.46) | MERTKTTK | |
| SCHEMBL4979267 | 0.83 | TTK (0.51) | MERTKCSF1RLRRK2TTKTYRO3 | |
| SCHEMBL4979599 | 0.82 | MERTK (0.51) | MERTKCSF1RTTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | MERTK 1662/4885CSF1R 4296/4885PLK4 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.